Bevacizumab/capecitabine/oxaliplatin
1
Reactions 1455 - 8 Jun 2013 Bevacizumab/capecitabine/oxaliplatin Nausea and diarrhoea: case report A 60-year-old man developed nausea and diarrhoea while receiving bevacizumab, capecitabine and oxaliplatin. The man, who had sigmoid colon cancer with liver metastases, started receiving neoadjuvant chemotherapy with the XELOX protocol consisting of capecitabine 1000 mg/m 2 and oxaliplatin 130 mg/m 2 [routes not stated]. After the first cycle, he continued to receive the XELOX protocol with the addition of bevacizumab 7.5 mg/kg [route not stated]. After the second cycle of treatment, he experienced grade 2 nausea and diarrhoea. The man continued to receive chemotherapy; he received nine cycles of XELOX and bevacizumab, before undergoing liver resection. Author comment: "Although nausea and diarrhoea (both Grade 2) were observed after the second cycle, the chemotherapy was continued as scheduled with almost no dose reductions or discontinuation." Hisatsune Y, et al. A patient who showed a pathologically complete response after undergoing treatment with XELOX plus bevacizumab for synchronous liver metastasis of grade H2 from sigmoid colon cancer. Journal of Gastrointestinal Oncology 4: E5-E10, No. 2, Jun 2013. Available from: URL: http:// dx.doi.org/10.3978/j.issn.2078-6891.2012.060 - Japan 803088123 1 Reactions 8 Jun 2013 No. 1455 0114-9954/10/1455-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Bevacizumab/capecitabine/oxaliplatin
Reactions 1455 - 8 Jun 2013
Bevacizumab/capecitabine/oxaliplatin
Nausea and diarrhoea: case reportA 60-year-old man developed nausea and diarrhoea while
receiving bevacizumab, capecitabine and oxaliplatin.The man, who had sigmoid colon cancer with liver
metastases, started receiving neoadjuvant chemotherapy withthe XELOX protocol consisting of capecitabine 1000 mg/m2
and oxaliplatin 130 mg/m2 [routes not stated]. After the firstcycle, he continued to receive the XELOX protocol with theaddition of bevacizumab 7.5 mg/kg [route not stated]. After thesecond cycle of treatment, he experienced grade 2 nausea anddiarrhoea.
The man continued to receive chemotherapy; he receivednine cycles of XELOX and bevacizumab, before undergoingliver resection.
Author comment: "Although nausea and diarrhoea (bothGrade 2) were observed after the second cycle, thechemotherapy was continued as scheduled with almost nodose reductions or discontinuation."Hisatsune Y, et al. A patient who showed a pathologically complete response afterundergoing treatment with XELOX plus bevacizumab for synchronous livermetastasis of grade H2 from sigmoid colon cancer. Journal of GastrointestinalOncology 4: E5-E10, No. 2, Jun 2013. Available from: URL: http://dx.doi.org/10.3978/j.issn.2078-6891.2012.060 - Japan 803088123
1
Reactions 8 Jun 2013 No. 14550114-9954/10/1455-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
